1502P - Insomnia prevalence in an oncology patient population: an Irish tertiary referral centre experience

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Supportive Measures
Presenter Emily Harrold
Citation Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390
Authors E.C. Harrold1, A.F. Idris2, N.M. Keegan3, L. Corrigan4, M.Y. Teo5, S.T. Lim6, E. Duff6, M. O Donnell6, J. Kennedy7, D. O'Donnell8, S. Sukor4, C. Grant4, D. Gallagher4, S. Collier2, T. Kingston2, A.M. O'Dwyer2, S. Cuffe4
  • 1Dept Medical Oncology, Mater Hospital, 0000 - Dublin/IE
  • 2Department Of Medical Oncology, St James's Hospital, 8 - Dublin/IE
  • 3Medical Oncology, Beaumont Hospital, Dublin/IE
  • 4Medical Oncology, St James's Hospital, Dublin/IE
  • 5Medical Oncology, Memorial Sloan Kettering Cancer Center, NY 10065 - New York/US
  • 6Medicine, Trinity College Dublin, Dublin 2 - Dublin/IE
  • 7Medical Oncology, St James's Hospital, 8 - Dublin/IE
  • 8Haematology Oncology Day Care Centre, St James's Hospital, 8 - Dublin/IE



NCCN survivorship guidelines recommend dedicated sleep assessment reflecting its association with increased symptom distress scores and mortality Reported insomnia prevalence in the general Irish population is 15%; reported prevalence internationally amongst new or recently diagnosed cancer patients varies from 23-50%. Insomnia prevalence has not been quantified in an Irish oncology cohort.


With ethical approval an 8 page questionnaire was prospectively administered to ambulatory cancer patients aged ≥ 18 attending a tertiary referral centre. Pre-specified criteria for insomnia syndrome (IS) combined those of International Classification of Sleep Disorders and DSM-IV. The Hospital Anxiety and Depression scale (HADS-D/A) was used to screen for depression and anxiety as confounding variables. Logistical regression model was used for analysis.


Response rate was 87% (294/337). Median respondent age was 55-64.80% were female. Breast (37%), colorectal (13%) and lung (12.2%) were the most common cancer subtypes. 62% reported sleep disturbance after diagnosis.33% met IS criteria. 60% reported moderate/severe insomnia related distress, 23% a significant impact on physical function. 45% who did not meet criteria had ≥1 of 4 critical features. On univariate analysis female sex, age


Insomnia prevalence in this Irish cohort is comparable to that previously reported and sleep assessment is justified. Alcohol is a modifiable risk factor independently predicting IS. HADS-D/A ≥11 increased OR of IS demonstrating additional utility of this scale. A patient education leaflet on sleep management is in progress to incorporate and reinforce our findings

Clinical trial identification

Legal entity responsible for the study

Dr Emily Harrold




All authors have declared no conflicts of interest.